3 September 2021 - Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukaemia, has taken a step closer to winning health insurance benefits.
On Friday, the Health Insurance Review and Assessment Service (HIRA) released the result of the drugs benefit appraisal committee’s meeting on Xospata’s eligibility for reimbursement.